Clinical Implications

Preclinical and clinical evidence suggests a role for MET activation as both a primary oncogenic driver in subsets of lung cancer and as a secondary driver of acquired resistance to targeted therapy. MET gene amplification is associated with acquired resistance to EGFR inhibitors and several monoclonal antibodies and small-molecule inhibitors of MET have been evaluated in clinical trials. In patients with advanced non-small-cell lung cancer, small-molecule inhibitors of MET, showed clear efficacy with a generally tolerable adverse events profile.

Specimen Requirements

Acceptable specimens for the assay are formalin (10% buffered formalin)-fixed (6-48 hours), paraffin-embedded lung tissue specimens. Sectioned slides must be analyzed within 24 months after sectioning date.

Volume

One representative paraffin block is preferred. Alternatively, 3 unstained freshly sectioned tissue sections of 4 µm thickness on positively charged slides are accepted (1 slide for H&E staining, 2 slides for MET FISH testing)

Storage and Shipment Instructions

Maintain and ship specimens at ambient temperature.

Limitations

Fixatives other than buffered formalin, prolonged fixation time, decalcification, or exposure to severe heat or chemicals may give rise to inadequate results.

Turn-Around Time

Five to seven business days for slides and paraffin blocks respectively.